Insulet

PODD - InsuletFinancials

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2016
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2017
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
1,697
293
-
12%
2.8
733
28%
662
2.3
97
-109
-14
-12
-13
0
-
-
12/2024
2,072
390
-
20%
5.7
1,212
35%
343
0.88
361
-134
-28
227
-8
0
-
-
12/2025
2,708
564
-
9%
3.4
1,515
16%
215
0.38
507
-219
-595
287
-85
0
-
-